Wonil Kim
Chief Scientific Officer Aston Sci
As the Chief Scientific Officer of Aston Sci. Inc., the biotech company, Dr. Wonil Kim spearheads strategic R&D focused on an AI-driven epitope prediction platform, Th-Vac, to create therapeutic anti-cancer or prophylactic anti-virus vaccines. His work emphasizes educating Th1 cells through mRNA vaccines and developing advanced immuno-oncological therapies. Wonil has built an mRNA drug R&D platform targeting cancer, viral infections, and autoimmune diseases. This platform leverages innovations in vitro transcription, large-scale mRNA production, FPLC/HPLC purification, and mRNA-lipid nanoparticle (LNP) encapsulation in developing mRNA drug candidates, including preventive vaccines and immune therapeutics.
Seminars
Wednesday 9th December 2026
Exploring Applications of In Silico Screening to Enable Faster & More Precise Antigen Epitope Discovery for Cancer Vaccine Therapies
4:30 pm
- Utilizing in silico screening tools to enable faster and more precise antigen and drug discovery
- Leveraging in silico screening platforms to discover antigen epitopes for cancer vaccine therapies, validated with preclinical performance of clinical-stage pipeline
- Laying out development of novel mRNA-based cancer vaccines with antigen epitopes derived through in silico screening
